Effects of Serotonin Excess on Bone in Carcinoid Syndrome

Status Completed

Clinical Trial Summary

Serotonin has recently been identified as a major regulator of bone formation. Gut-derived serotonin inhibits bone formation, and early animal studies have shown that inhibition of gut-derived serotonin has anabolic effects on bone in ovariectomised rodents. This pathway has potential to be developed as a new anabolic treatment for osteoporosis in humans.

Carcinoid neuro-endocrine tumours produce very high levels of serotonin, and so it might be expected that patients with carcinoid disease would have reduced bone formation, low bone mass and fractures. However, this has not been apparent in clinical practice. There may be a discrepancy between rodent models and human disease. This study aims to identify whether patients with carcinoid disease have reduced bone mass, reduced bone formation or high fracture rates. The investigators will conduct a cross-sectional observational case-control study of patients with carcinoid disease in the Sheffield neuro-endocrine tumour clinic and gender-, age- and body mass index (BMI)-matched controls.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01430871
Study type	Observational
Source	Sheffield Teaching Hospitals NHS Foundation Trust
Contact
Status	Completed
Phase	N/A
Start date	January 2011
Completion date	November 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04993261` - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors	Early Phase 1
Not yet recruiting	`NCT04039516` - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	Phase 2
Completed	`NCT01234168` - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated	`NCT04073017` - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency	N/A
Recruiting	`NCT05756608` - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed	`NCT00774930` - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome	Phase 3
Withdrawn	`NCT04713202` - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl	Phase 2
Completed	`NCT00853047` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy	Phase 2
Completed	`NCT02063659` - Telotristat Etiprate for Carcinoid Syndrome Therapy	Phase 3
Withdrawn	`NCT04776876` - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome	Phase 2
Completed	`NCT03223428` - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting	`NCT03453489` - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm	Phase 2
Active, not recruiting	`NCT05361668` - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome	Phase 2
Completed	`NCT01104415` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome	Phase 2
Withdrawn	`NCT01172717` - Study of Panitumumab in the Treatment of Carcinoid Syndrome	Phase 2
Terminated	`NCT00884715` - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome	Phase 1/Phase 2
Completed	`NCT01677910` - TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)	Phase 3
Completed	`NCT02026063` - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms	Phase 3
Terminated	`NCT01018953` - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome	Phase 2
Terminated	`NCT04140409` - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation	Phase 4